Immunogenicity Summit

Overview

A 2-part event covering developments in assay technologies, pre-clinical and clinical immunogenicity, risk assessment, regulatory guidance and means of predicting and avoiding Immunogenicity.

Following year-on-year success, our fourth Immunogenicity Summit will continue to provide strong interaction and discussion with the regulatory authorities (40 FDA representatives in 2011), updates on immunogenicity testing, pre-clinical and clinical strategies, and factors that contribute to immunogenicity including aggregates and sub-visible particles.

New this year will be a strong focus on the impact of immunogenicity on PKPD, the relationship between immune complexes and immunogenicity, immunogenicity for biosimilars, predictive methods for immunogenicity, and immune tolerance approaches.

Who Will Attend

Directors, Team Leaders, Project Managers, Heads, Senior Scientists, Principal Scientists, Research Scientists, Research Associates, and Managers working at Pharmaceutical, Biotechnology and Academic/Government Organizations and working in:

  • Immunogenicity
  • Immunology
  • Biotherapeutics
  • Monoclonal Antibodies
  • Clinical Pharmacology
  • Immunotoxicology
  • Immunoassay
  • Medical Affairs
  • Drug Safety
  • Clinical Testing
  • Bioanalytical Sciences
  • Infectious Diseases
  • Protein Analysis
  • External Scientific Affairs
  • Bioanalysis
  • Assay Development
  • Biomarkers
  • Pre-Clinical and Clinical Development
  • Clinical Affairs
  • R&D
  • Regulatory Affairs
  • PKPD
2011 Attendee Profile by Function



Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 


2014 Brochure Cover

Download Brochure 

Premier Sponsor : 


 Charles River(1) 



Podcast 

IMN Podcast iconReducing and Monitoring Bioassay Variability 

2013 Speaker: Janet L. Lathey, Ph.D., Director, Immunology and Assay Development, BioDefenseDivision, Emergent BioSolutions